Zhao Jianping
General Manager, Beijing Xi'nuoyin Biotech Co
With 24 years of experience, Zhao Jianping has primarily been involved in the fields of bioscience, biomedicine, and medical equipment.
In 2014, as a co-founder, he joined Beijing SINOGENE Biotech Co to conduct research and development of cloning and gene editing technology for dogs.
In 2017, a technological breakthrough was achieved with the successful creation of China's first somatic cell cloned dog "Longlong" using independent technology, and also the world's first gene-edited cloned dog, combining dog gene editing technology.
As the company's technical leader, he has established and improved the SINOGENE's animal (dog/cat/horse/pig/cattle) cloning and gene editing technology platforms, and developed a series of original technical innovations.